Klimed MK Sp. z o.o.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease2 trials
• Atopic dermatitis (eczema)1 trial
• Atrial fibrillation1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Heart failure1 trial
• Metastatic breast cancer1 trial
• Obesity1 trial
• Stroke1 trial
• Ulcerative colitis1 trial

Phase

• Phase 36 trials
• Phase 22 trials
• Phase 11 trial

Status

• Completed7 trials
• Active, not recruiting2 trials

Lead sponsor

• Eli Lilly and Company3 trials
• AriBio Co., Ltd.1 trial
• Bayer AG1 trial
• Pfizer1 trial
• Pfizer Inc.1 trial
• and 2 more

Running trials

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· AriBio Co., Ltd.· Source

Closed trials

• Completed

  A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC.

  NCT05549323· Phase 1· Pfizer Inc.· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Eli Lilly and Company· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

  NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source

• Completed

  To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT04684485· Phase 2· Sun Pharmaceutical Industries Limited· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source